DK1189620T3 - Formulering indeholdende testosteronundecanoat og amerikansk olie - Google Patents

Formulering indeholdende testosteronundecanoat og amerikansk olie

Info

Publication number
DK1189620T3
DK1189620T3 DK00920588T DK00920588T DK1189620T3 DK 1189620 T3 DK1189620 T3 DK 1189620T3 DK 00920588 T DK00920588 T DK 00920588T DK 00920588 T DK00920588 T DK 00920588T DK 1189620 T3 DK1189620 T3 DK 1189620T3
Authority
DK
Denmark
Prior art keywords
testosterone undecanoate
solution
liquid carrier
formulation containing
american oil
Prior art date
Application number
DK00920588T
Other languages
Danish (da)
English (en)
Inventor
De Henrik Nijs
Susan Chandler
Elizabeth Anne Perry
Josephine Joan Chri Ferdinando
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of DK1189620T3 publication Critical patent/DK1189620T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DK00920588T 1999-04-01 2000-03-27 Formulering indeholdende testosteronundecanoat og amerikansk olie DK1189620T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99302581 1999-04-01

Publications (1)

Publication Number Publication Date
DK1189620T3 true DK1189620T3 (da) 2004-08-16

Family

ID=8241306

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00920588T DK1189620T3 (da) 1999-04-01 2000-03-27 Formulering indeholdende testosteronundecanoat og amerikansk olie

Country Status (27)

Country Link
EP (1) EP1189620B1 (zh)
JP (1) JP2002541111A (zh)
KR (1) KR100666016B1 (zh)
CN (1) CN1155385C (zh)
AT (1) ATE269708T1 (zh)
AU (1) AU768537B2 (zh)
BR (1) BR0009465A (zh)
CA (1) CA2366856C (zh)
CZ (1) CZ298573B6 (zh)
DE (1) DE60011771T2 (zh)
DK (1) DK1189620T3 (zh)
ES (1) ES2222199T3 (zh)
HK (1) HK1043544A1 (zh)
HU (1) HU229455B1 (zh)
ID (1) ID30481A (zh)
IL (2) IL145524A0 (zh)
MX (1) MXPA01009919A (zh)
NO (1) NO329420B1 (zh)
NZ (1) NZ514290A (zh)
PL (1) PL195163B1 (zh)
PT (1) PT1189620E (zh)
RU (1) RU2246296C2 (zh)
SK (1) SK286071B6 (zh)
TR (1) TR200102769T2 (zh)
TW (1) TWI280124B (zh)
WO (1) WO2000059512A1 (zh)
ZA (1) ZA200107781B (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6652880B1 (en) 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
ES2258694T3 (es) * 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
US20060140820A1 (en) 2004-12-28 2006-06-29 Udo Mattern Use of a container of an inorganic additive containing plastic material
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
ES2930658T3 (es) 2005-04-15 2022-12-20 Tolmar Inc Sistemas de administración farmacéutica para medicamentos hidrofóbicos y composiciones que comprenden los mismos
KR101307133B1 (ko) 2006-10-04 2013-09-12 엠엔피 페이턴트 악티엔게젤샤프트 신경전달물질의 비강 투여를 위한 서방형 전달 시스템
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
CN102883710B (zh) * 2010-04-12 2014-09-10 克劳拉斯医疗有限公司 口服睾酮酯制剂以及包含其的治疗睾酮缺乏症的方法
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CN109700763A (zh) * 2011-01-26 2019-05-03 阿勒根公司 用于治疗眼科病症的雄性激素组合物
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
AU2015276321B2 (en) 2014-06-17 2019-10-24 Merck Sharp & Dohme B.V. Stable formulations of testosterone undecanoate
PL3157508T3 (pl) * 2014-06-19 2021-05-17 Solural Pharma ApS Związki lipofilowe w postaci stałej dawkowane doustnie
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160193225A1 (en) * 2014-08-29 2016-07-07 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL UNDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1102095A (zh) * 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
GB9608719D0 (en) * 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE9700642D0 (sv) * 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet

Also Published As

Publication number Publication date
MXPA01009919A (es) 2002-04-24
TR200102769T2 (tr) 2002-05-21
HUP0200453A2 (hu) 2002-07-29
PT1189620E (pt) 2004-10-29
CA2366856A1 (en) 2000-10-12
KR100666016B1 (ko) 2007-01-10
ATE269708T1 (de) 2004-07-15
DE60011771D1 (de) 2004-07-29
CZ298573B6 (cs) 2007-11-14
NO20014718D0 (no) 2001-09-28
ZA200107781B (en) 2002-12-20
JP2002541111A (ja) 2002-12-03
HU229455B1 (en) 2013-12-30
CN1155385C (zh) 2004-06-30
SK286071B6 (sk) 2008-02-05
HK1043544A1 (en) 2002-09-20
IL145524A (en) 2006-12-31
CN1346274A (zh) 2002-04-24
RU2246296C2 (ru) 2005-02-20
SK13722001A3 (sk) 2002-02-05
NO20014718L (no) 2001-09-28
DE60011771T2 (de) 2004-11-04
CA2366856C (en) 2006-05-16
EP1189620A1 (en) 2002-03-27
HUP0200453A3 (en) 2003-06-30
ES2222199T3 (es) 2005-02-01
KR20010108435A (ko) 2001-12-07
NZ514290A (en) 2003-08-29
WO2000059512A1 (en) 2000-10-12
BR0009465A (pt) 2002-01-08
TWI280124B (en) 2007-05-01
NO329420B1 (no) 2010-10-18
PL351259A1 (en) 2003-04-07
EP1189620B1 (en) 2004-06-23
IL145524A0 (en) 2002-06-30
ID30481A (id) 2001-12-13
PL195163B1 (pl) 2007-08-31
AU768537B2 (en) 2003-12-18
AU4111100A (en) 2000-10-23
CZ20013507A3 (cs) 2002-03-13

Similar Documents

Publication Publication Date Title
DK1189620T3 (da) Formulering indeholdende testosteronundecanoat og amerikansk olie
RU2001129362A (ru) Композиция, включающая ундеканоат тестостерона и касторовое масло
DK1173153T3 (da) Orale farmaceutiske præparater, som indeholder langkædede triglycerider og lipofile overfladeaktive midler
HK1080364A1 (en) Oral pharmaceutical forms of liquid drugs having improved bioavailability
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
PL318560A1 (en) Novel orally administered preparations containing cyclosporin of simple composition and high bioavailability
CA2185347A1 (en) A carrier for hydrophobic drugs and a pharmaceutical composition based thereon
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
CA2304704A1 (en) Formulations and methods for reducing toxicity of antineoplastic agents
CO5560580A2 (es) Formulaciones de sucralosa para disumular sabores desagradables
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
NO950134L (no) Formuleringer for oralt administrerte farmasöytiske midler
MXPA04000535A (es) FORMULACIONES ANTIHISTAMINICAS PARA FORMAS DE DOSIFICACION DE CaPSULAS SUAVES.
CO4970832A1 (es) Nuevas formulaciones y procesos para su fabricacion
MXPA05008921A (es) Formulaciones orales semisolidas para liberacion inmediata que comprenden un agente hidrofobo anticancer, un glicerido poliglicolisado y un vehiculo hidrofilo.
AR023235A1 (es) Formulaciones de androgenos
US20060024341A1 (en) Microemulsion composition and related method
TH33003B (th) สูตรตำรับแอนโดรเจน
TH60756A (th) สูตรตำรับแอนโดรเจน
TH34374B (th) องค์ประกอบเชิงเภสัชกรรมชนิดที่เป็นของแข็งซึ่งประกอบด้วยอนุพันธ์เบนโซฟูแรน
TH40043A (th) องค์ประกอบเชิงเภสัชกรรมชนิดที่เป็นของแข็งซึ่งประกอบด้วยอนุพันธ์เบนโซฟูแรน
MY130474A (en) Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants